New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

被引：5
作者：
Wang, Yanjun [1 ]
Yang, Shuo [2 ,3 ]
Wan, Li [4 ]
Ling, Wei [2 ]
Chen, Hao [5 ]
Wang, Jinghua [2 ]
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Urol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510062, Guangdong, Peoples R China
[2] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Hematol, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Peking Univ, Shenzhen Hosp, Dept Gastroenterol, Shenzhen 518036, Guangdong, Peoples R China
[4] Wuhan Univ, Renmin Hosp, Dept Endocrinol & Metab, Wuhan 430060, Hubei, Peoples R China
[5] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gastroenterol, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF ONCOLOGY | 2023年 / 63卷 / 01期
基金：
中国国家自然科学基金;
关键词：
immune checkpoint inhibitors; immunotherapy; T cells; cancer; biomarkers; CELL LUNG-CANCER; TUMOR-INFILTRATING LYMPHOCYTES; REGULATORY T-CELLS; RESISTANT PROSTATE-CANCER; PROGRAMMED DEATH 1; LONG-TERM SAFETY; PD-1; BLOCKADE; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; ADVANCED MELANOMA;
D O I：
10.3892/ijo.2023.5534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of immune checkpoint inhibitors (ICIs) has been demonstrated in the treatment of numerous types of cancer and ICIs have remained a key focus of cancer research. However, improvements in survival rates only occur in a subset of patients, due to the complexity of drug resistance. Therefore, further investigations are required to identify predictive biomarkers that distinguish responders and non-responders. Combined therapeutics involving ICIs and other modalities demonstrate potential in overcoming resistance to ICIs; however, further preclinical and clinical trials are required. Concurrently, prompt recognition and intervention of immune-related adverse events are crucial to optimize the use of ICIs in clinical treatment. The present study aimed to review the current literature surrounding the mechanisms and application of ICIs, with the aim of providing a theoretical basis for clinicians.
引用
收藏
页数：19
相关论文
共 262 条
  • [1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria E.
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    Adams, Sylvia
    Gray, Robert J.
    Demaria, Sandra
    Goldstein, Lori
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Wang, Molin
    Jones, Vicky E.
    Saphner, Thomas J.
    Wolff, Antonio C.
    Wood, William C.
    Davidson, Nancy E.
    Sledge, George W.
    Sparano, Joseph A.
    Badve, Sunil S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 2959 - +
  • [3] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
    Agata, Y
    Kawasaki, A
    Nishimura, H
    Ishida, Y
    Tsubata, T
    Yagita, H
    Honjo, T
    [J]. INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) : 765 - 772
  • [4] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Ahmadzadeh, Mojgan
    Johnson, Laura A.
    Heemskerk, Bianca
    Wunderlich, John R.
    Dudley, Mark E.
    White, Donald E.
    Rosenberg, Steven A.
    [J]. BLOOD, 2009, 114 (08) : 1537 - 1544
  • [5] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [6] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [7] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
    Amaria, Rodabe N.
    Reddy, Sangeetha M.
    Tawbi, Hussein A.
    Davies, Michael A.
    Ross, Merrick, I
    Glitza, Isabella C.
    Cormier, Janice N.
    Lewis, Carol
    Hwu, Wen-Jen
    Hanna, Ehab
    Diab, Adi
    Wong, Michael K.
    Royal, Richard
    Gross, Neil
    Weber, Randal
    Lai, Stephen Y.
    Ehlers, Richard
    Blando, Jorge
    Milton, Denai R.
    Woodman, Scott
    Kageyama, Robin
    Wells, Daniel K.
    Hwu, Patrick
    Patel, Sapna P.
    Lucci, Anthony
    Hessel, Amy
    Lee, Jeffrey E.
    Gershenwald, Jeffrey
    Simpson, Lauren
    Burton, Elizabeth M.
    Posada, Liberty
    Haydu, Lauren
    Wang, Linghua
    Zhang, Shaojun
    Lazar, Alexanderj
    Hudgens, Courtney W.
    Gopalakrishnan, Vancheswaran
    Reuben, Alexandre
    Andrews, Miles C.
    Spencer, Christine N.
    Prieto, Victor
    Sharma, Padmanee
    Allison, James
    Tetzlaff, Michael T.
    Wargo, Jennifer A.
    [J]. NATURE MEDICINE, 2018, 24 (11) : 1649 - +
  • [8] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
    Anderson, Ana C.
    Joller, Nicole
    Kuchroo, Vijay K.
    [J]. IMMUNITY, 2016, 44 (05) : 989 - 1004
  • [9] Tim-3, a negative regulator of anti-tumor immunity
    Anderson, Ana Carrizosa
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 213 - 216
  • [10] LAG3 (CD223) as a cancer immunotherapy target
    Andrews, Lawrence P.
    Marciscano, Ariel E.
    Drake, Charles G.
    Vignali, Dario A. A.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 80 - 96
12345678910